ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News

A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation

Phase 3
Completed
Conditions
Kidney Transplantation
Interventions
Drug: tacrolimus
First Posted Date
2005-09-19
Last Posted Date
2014-07-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
699
Registration Number
NCT00189839

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

First Posted Date
2005-09-19
Last Posted Date
2008-01-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT00189709

A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.

Phase 3
Completed
Conditions
Liver Transplantation
Interventions
Drug: tacrolimus
First Posted Date
2005-09-19
Last Posted Date
2014-07-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
475
Registration Number
NCT00189826

Community Based Trial for AMEVIVE®

Phase 4
Completed
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Drug: Alefacept
First Posted Date
2005-09-15
Last Posted Date
2014-09-08
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
114
Registration Number
NCT00168753
Locations
🇺🇸

Michael Scannon, Tampa, Florida, United States

🇺🇸

Calumet Dermatology Associates, Calumet City, Illinois, United States

🇺🇸

Skin and Cancer Associates, Tamarac, Florida, United States

and more 33 locations

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

First Posted Date
2005-09-12
Last Posted Date
2017-06-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
111
Registration Number
NCT00157014

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

Phase 2
Completed
Conditions
Gastroesophageal Reflux
First Posted Date
2005-09-02
Last Posted Date
2011-11-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
480
Registration Number
NCT00141960

Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection

First Posted Date
2005-08-23
Last Posted Date
2014-09-08
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
85
Registration Number
NCT00133172

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Phase 3
Completed
Conditions
Atrial Flutter
Atrial Fibrillation
First Posted Date
2005-08-01
Last Posted Date
2007-12-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
190
Registration Number
NCT00125320

A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

Phase 2
Completed
Conditions
Asthma
First Posted Date
2005-06-28
Last Posted Date
2012-06-07
Lead Sponsor
Astellas Pharma Inc
Registration Number
NCT00116103

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

First Posted Date
2005-06-27
Last Posted Date
2008-04-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
276
Registration Number
NCT00115791
Locations
🇸🇪

Investigative Site, Uppsala, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy